Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.92 USD | +1.41% | +4.21% | +5.21% |
Financials (USD)
Sales 2024 * | 239K | Sales 2025 * | 8.8M | Capitalization | 164M |
---|---|---|---|---|---|
Net income 2024 * | -119M | Net income 2025 * | -147M | EV / Sales 2024 * | 65.6 x |
Net cash position 2024 * | 149M | Net cash position 2025 * | 136M | EV / Sales 2025 * | 3.28 x |
P/E ratio 2024 * |
-1.26
x | P/E ratio 2025 * |
-1.39
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.21% |
Latest transcript on Adverum Biotechnologies, Inc.
1 day | +1.41% | ||
1 week | +4.21% | ||
1 month | -20.80% | ||
3 months | -59.80% | ||
6 months | -4.29% | ||
Current year | +5.21% |
Managers | Title | Age | Since |
---|---|---|---|
Laurent Fischer
CEO | Chief Executive Officer | 60 | 20-06-14 |
Linda Rubinstein
DFI | Director of Finance/CFO | 58 | 22-12-11 |
Bill Tan
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Whitcup
BRD | Director/Board Member | 64 | 20-04-15 |
Clarence Machado
CHM | Chairman | 60 | 17-03-13 |
Laurent Fischer
CEO | Chief Executive Officer | 60 | 20-06-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 7.92 | +1.41% | 295,956 |
24-05-30 | 7.81 | -2.62% | 61,784 |
24-05-29 | 8.02 | +4.70% | 182,138 |
24-05-28 | 7.66 | +0.79% | 256,041 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.21% | 164M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
+0.09% | 21.96B | |
-8.24% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ADVM Stock